Drug Profile


Alternative Names: SARC 023; STA-9090

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Cancer Research UK; Cardiff University; Emory University; Innsbruck Medical University; Madrigal Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; Synta Pharmaceuticals
  • Class Antineoplastics; Indoles; Resorcinols; Small molecules; Triazoles
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Non-small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase II Breast cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Small cell lung cancer
  • Phase I/II Fallopian tube cancer; Mesothelioma; Peritoneal cancer; Sarcoma
  • Phase I Chronic myeloid leukaemia; Colorectal cancer; Hepatocellular carcinoma; Multiple myeloma; Rectal cancer
  • Clinical Phase Unknown Head and neck cancer
  • Preclinical Neuroendocrine tumours
  • No development reported Gastric cancer; Gastrointestinal stromal tumours; Liver cancer; Prostate cancer
  • Discontinued Pancreatic cancer

Most Recent Events

  • 05 Dec 2016 Medical University Innsbruck suspends enrolment in a phase-I/II clinical trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in Austria, Belgium, France and Germany (IV) (NCT02012192)
  • 01 Dec 2016 Synta terminates a phase II/III trial in Myelodysplastic syndromes, acute myeloid leukaemia and acute lymphoblastic leukaemia (combination therapy, in elderly) due to the drug company no longer supporting ganetespib in France, United Kingdom, Denmark, New Zealand and Australia (IV)
  • 12 Oct 2016 Georgetown University terminates a phase I/II trial in Small cell lung cancer (Second line therapy or greater) in USA due to the termination of dug support by the company (NCT02261805)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top